{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T15:38:59Z","timestamp":1764603539551,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Incyte Corp","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-5100-4","type":"journal-article","created":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T08:50:10Z","timestamp":1544172610000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Ponatinib induces a sustained deep molecular response in a chronic myeloid leukaemia patient with an early relapse with a T315I mutation following allogeneic hematopoietic stem cell transplantation: a case report"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5098-3840","authenticated-orcid":false,"given":"Nuno","family":"Cerveira","sequence":"first","affiliation":[]},{"given":"Rosa Branca","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"Susana","family":"Bizarro","sequence":"additional","affiliation":[]},{"given":"Cec\u00edlia","family":"Correia","sequence":"additional","affiliation":[]},{"given":"Lurdes","family":"Torres","sequence":"additional","affiliation":[]},{"given":"Susana","family":"Lisboa","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Vieira","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Santos","sequence":"additional","affiliation":[]},{"given":"Fernando","family":"Campilho","sequence":"additional","affiliation":[]},{"given":"Carlos","family":"Pinho Vaz","sequence":"additional","affiliation":[]},{"given":"Lu\u00eds","family":"Leite","sequence":"additional","affiliation":[]},{"given":"Manuel R.","family":"Teixeira","sequence":"additional","affiliation":[]},{"given":"Ant\u00f3nio","family":"Campos","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2018,12,7]]},"reference":[{"issue":"15","key":"5100_CR1","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMra020777","volume":"349","author":"JM Goldman","year":"2003","unstructured":"Goldman JM, Melo JV. Chronic myeloid leukemia: advances in biology and new approaches to treatment. N Engl J Med. 2003;349(15):1451\u201364.","journal-title":"N Engl J Med"},{"issue":"9","key":"5100_CR2","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1182\/blood.V76.9.1819.1819","volume":"76","author":"G Saglio","year":"1990","unstructured":"Saglio G, Guerrasio A, Rosso C, Zaccaria A, Tassinari A, Serra A, et al. New type of Bcr\/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 1990;76(9):1819\u201324.","journal-title":"Blood"},{"issue":"4","key":"5100_CR3","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1046\/j.1365-2141.2000.02471.x","volume":"111","author":"GA Wilson","year":"2000","unstructured":"Wilson GA, Vandenberghe EA, Pollitt RC, Rees DC, Goodeve AC, Peake IR, et al. Are aberrant BCR-ABL transcripts more common than previously thought? Br J Haematol. 2000;111(4):1109\u201311.","journal-title":"Br J Haematol"},{"issue":"4","key":"5100_CR4","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.hemonc.2016.05.007","volume":"9","author":"M Crampe","year":"2016","unstructured":"Crampe M, Garry J, Langabeer SE, Murphy PT. Sustained molecular response with nilotinib in imatinib-intolerant chronic myeloid leukaemia with an e19a2 BCR-ABL1 fusion. Hematol Oncol Stem Cell Ther. 2016;9(4):168\u20139.","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"7","key":"5100_CR5","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1038\/sj.leu.2401055","volume":"12","author":"GF How","year":"1998","unstructured":"How GF, Tan LT, Lim LC. Chronic myeloid leukemia with e19a2 (c3a2) BCR\/ABL fusion junction: is it truly a benign disease? Leukemia. 1998;12(7):1166\u20137.","journal-title":"Leukemia"},{"issue":"3","key":"5100_CR6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/hon.822","volume":"25","author":"H Andrikovics","year":"2007","unstructured":"Andrikovics H, Nahajevszky S, Szilv\u00e1si A, Bors A, Ad\u00e1m E, Kozma A, et al. First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts. Hematol Oncol. 2007;25(3):143\u20137.","journal-title":"Hematol Oncol"},{"issue":"5","key":"5100_CR7","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/bjh.15453","volume":"182","author":"YZ Qin","year":"2018","unstructured":"Qin YZ, Jiang Q, Jiang H, Lai YY, Shi HX, Chen WM, et al. Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single Centre. Br J Haematol. 2018;182(5):693\u2013700.","journal-title":"Br J Haematol"},{"issue":"6","key":"5100_CR8","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872\u201384.","journal-title":"Blood"},{"issue":"12","key":"5100_CR9","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","volume":"17","author":"J Gabert","year":"2003","unstructured":"Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe against Cancer program. Leukemia. 2003;17(12):2318\u201357.","journal-title":"Leukemia"},{"issue":"1","key":"5100_CR10","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","volume":"102","author":"S Branford","year":"2003","unstructured":"Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003;102(1):276\u201383.","journal-title":"Blood"},{"issue":"10","key":"5100_CR11","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","volume":"20","author":"E Jabbour","year":"2006","unstructured":"Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O'Brien S, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia. 2006;20(10):1767\u201373.","journal-title":"Leukemia"},{"issue":"10","key":"5100_CR12","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1182\/blood-2009-01-197715","volume":"114","author":"E Jabbour","year":"2009","unstructured":"Jabbour E, Jones D, Kantarjian HM, O'Brien S, Tam C, Koller C, et al. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood. 2009;114(10):2037\u201343.","journal-title":"Blood"},{"issue":"9","key":"5100_CR13","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1038\/leu.2015.168","volume":"29","author":"TP Hughes","year":"2015","unstructured":"Hughes TP, Saglio G, Quint\u00e1s-Cardama A, Mauro MJ, Kim DW, Lipton JH, et al. BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase. Leukemia. 2015;29(9):1832\u20138.","journal-title":"Leukemia"},{"issue":"6","key":"5100_CR14","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s12185-018-2422-6","volume":"107","author":"K Naqvi","year":"2018","unstructured":"Naqvi K, Cortes JE, Luthra R, O'Brien S, Wierda W, Borthakur G, et al. Characteristics and outcome of chronic myeloid leukemia patients with E255K\/V BCR-ABL kinase domain mutations. Int J Hematol. 2018;107(6):689\u201395.","journal-title":"Int J Hematol"},{"issue":"11","key":"5100_CR15","doi-asserted-by":"publisher","first-page":"E125","DOI":"10.1002\/ajh.23338","volume":"87","author":"S Redaelli","year":"2012","unstructured":"Redaelli S, Mologni L, Rostagno R, Piazza R, Magistroni V, Ceccon M, et al. Three novel patient-derived BCR\/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Am J Hematol. 2012;87(11):E125\u20138.","journal-title":"Am J Hematol"},{"issue":"16","key":"5100_CR16","doi-asserted-by":"publisher","first-page":"6082","DOI":"10.1128\/MCB.02202-05","volume":"26","author":"IJ Griswold","year":"2006","unstructured":"Griswold IJ, MacPartlin M, Bumm T, Goss VL, O'Hare T, Lee KA, et al. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol. 2006;26(16):6082\u201393.","journal-title":"Mol Cell Biol"},{"issue":"1","key":"5100_CR17","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/leu.2011.187","volume":"26","author":"FX Gruber","year":"2012","unstructured":"Gruber FX, Ernst T, Porkka K, Engh RA, Mikkola I, Maier J, et al. Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients. Leukemia. 2012;26(1):172\u20137.","journal-title":"Leukemia"},{"issue":"9","key":"5100_CR18","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1182\/blood-2013-03-487728","volume":"122","author":"S Soverini","year":"2013","unstructured":"Soverini S, De Benedittis C, Machova Polakova K, Brouckova A, Horner D, Iacono M, et al. Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. Blood. 2013;122(9):1634\u201348.","journal-title":"Blood"},{"key":"5100_CR19","volume-title":"ARIAD Pharma Ltd","author":"Iclusig (summary of product characteristics)","year":"2017","unstructured":"Iclusig (summary of product characteristics). ARIAD Pharma Ltd. UK: Leatherhead; 2017. \n                    https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/iclusig\n                    \n                  ."},{"issue":"3","key":"5100_CR20","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/ejh.12358","volume":"94","author":"CA Ferri","year":"2015","unstructured":"Ferri CA, Bianchini M, Bengi\u00f3 RM, Moiraghi EB, Gonzalez MS, Noriega MF, et al. Clinical activity of ponatinib in one patient with chronic myeloid leukemia in chronic phase with e19a2 transcript and T315I mutation. Eur J Haematol. 2015;94(3):270\u20132.","journal-title":"Eur J Haematol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-5100-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-5100-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-5100-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T19:10:56Z","timestamp":1575659456000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-5100-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["5100"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-5100-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"type":"electronic","value":"1471-2407"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"15 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study is in accordance with the ethical standards of the Ethics Committee of the Portuguese Oncology Institute of Porto (approval number 38.010) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"1229"}}